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Introduction
This component of the series on tuberculosis in primary care will focus on
laboratory diagnosis. Despite the advances in diagnosis described here, up
to 20% of U.S. tuberculosis cases are clinically diagnosed.1 Recommendations for the core laboratory features of a tuberculosis control program
include2 the following:
Rapid microscopic evaluation for acid-fast bacilli;
Nucleic acid amplification assay (NAA/polymerase chain reaction (PCR))
of collected sample;
Culture, with detection and subsequent identification of samples within 3
weeks (which presupposes use of automated broth culture methods);
and,
Drug susceptibility testing for both first- and second-line drugs (usually
performed at the state lab or national referral center level).
The evidence on laboratory diagnosis of tuberculosis allows a systematic approach to testing in a given patient (Fig 1). Details regarding
specimen collection and handling for various anatomic sites are published.3,4 Note that while some settings enjoy a high diagnostic yield by
laboratory methods, no modality is sufficient in isolation. Smear and
culture-negative tuberculosis is a common phenomenon.5 CDC surveillance data from 2004 reveals 42% smear-negative and 17% culturenegative rates for pulmonary tuberculosis.1 Smear-negative index cases
contribute to as much as 17% of newly transmitted cases.6

Bacteriology and Microscopy
Tuberculosis is caused by a bacillus of the Mycobacterium tuberculosis
complex. The most common of the group, M. tuberculosis, is a respiratory
pathogen communicable between infected humans. While different auDis Mon 2006;52:450-458
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Suspected case of tuberculosis.

Pulmonary disease is suspected.

Other than pulmonary disease is suspected.

Send:
1. Three induced or spontaneous (respiratory isolation) a.m. sputum samples for
AFB staining and microscopy;
- 5 to 10 mL each, accept watery specimens
2. One sputum sample for MTb complex PCR;
3. Same three sputum samples for culture;
4. If effusion is present, consider sending diagnostic thoracentesis sample for
smear, culture, PCR, and adenosine deaminase (ADA) testing- pleural biopsy has
higher culture sensitivity;
5.Consider early morning gastric aspiration of 50 mL in children or failed
sputum inductions; and,
6.Consider an IFN based assay on serum or Tuberculin Skin Test- negative test
does not exclude disease.

Send:
1.Samples as you would for suspected pulmonary disease; and,
2.Sample from suspected site. For tissue collections, collect both with and without formalin.
a.Lymph node
-excisional biopsy preferred
-fine needle aspiration if unable to obtain excisional biopsy, e.g. CT guided
biopsy in setting of mesenteric adenitis
-AFB smear and culture
-histopathologic analysis
b.CSF
-cell count and differential
- chemistries to include glucose and protein
- AFB smear (typically negative) and culture (10 mL often required)
- consider PCR
c.Pleural, pericardial, or ascitic fluid
-cell count and differential
- chemistries to include glucose and protein
-AFB smear and culture (lining biopsies have higher yield)
-consider ADA analysis
-PCR
d.Other tissues (bone marrow, skin, liver, spleen, ..., kidney)
- AFB smear and culture
- histopathologic analysis, may consider specialized AFB staining, and
subsequent targeted PCR
-PCR
e.
Blood
- culture
- PCR
f.Stool, consider intestinal biopsy
- culture
- PCR
g.Urine (first morning mid-void stream collection), three daily samples
- urinalysis and conventional culture
- culture
- PCR

FIG 1. Clinical algorithm for the laboratory diagnosis of tuberculosis.

thors cite a variety of members in the group based upon varying
molecular and biochemical criteria, the most commonly accepted grouping includes M. tuberculosis, M. microti, M. africanum, M. bovis, and M.
canetti. The organisms grow slowly and stain acid fast because of a highly
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lipid and peptidoglycan-rich cell wall.7 Evaluation of sputum smears and
tissue samples is accomplished with two main stains: Ziehl–Neelsen and
auramine orange fluorescence.3
A large, prospective study was conducted to evaluate the operational
clinical performance of various technologies.8 Auramine orange fluorescence staining of three sputum samples per patient detected 7 of every 10
cases. The false-positive rate was 2 in 10. In other studies with
culture-proven disease, a single sputum sample detected disease in
one-half to two-thirds of cases, while three or four specimens detected as
many as 9 of every 10 cases.9,10 Most of the advantage in testing serial
sputum specimens is gained with the second specimen collected. While
spontaneous sputum samples are employed in many settings, use of
induced sputum sampling confers an advantage.11 Both watery and
viscous samples should be tested.
In most cases bronchoscopy for lavage is not required. It may be
appropriate when sputum smears are negative in the setting of a known
radiographic lesion allowing focused lavage. Induced sputum collection
and bronchoalveolar lavage can be used together, detecting 8 of 10
patients.12 Simple instructions and coaxing can dramatically increase
sputum smear yield.13
Auramine staining of sputum is superior.14,15 It has greater sensitivity
with a requirement for fewer screened microscopic fields as a lower
magnification can be used. Stain superiority in tissue samples is not
clear.16,17 Typically, 104 to 106 organisms/ml are required for detection,3,15 although concentration techniques can lower this number.
The hallmark finding on histopathology is the necrotizing or caseating
granuloma. When found, tuberculosis should be presumed until disproven. The number of granulomas observed may vary by biopsy
site— high numbers in the lung, low numbers in the bone marrow.18
Nontuberculosis mycobacteria also may cause necrotizing granulomas.
HIV status may affect the observed histopathology of biopsy samples.19

Culture
Culture remains the gold standard for diagnosis. Egg-based plate media
such as Löwenstein–Jensen are used, but agar media such as Selective
7H11 and liquid-based media (Becton–Dickinson and Co., BACTEC™
and BACTEC™ MGIT™) now are the standard. Some centers use all of
these modalities to capture rare strains.3 Growth in liquid mediaautomated detection systems is monitored by radiometric, colorimetric, or
pressure monitoring. Growth often can be detected within 2 weeks.
Typical hold periods are for 4 to 6 weeks. Use of these systems also
452
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allows expeditious drug susceptibility assessment when agents are added
into the liquid media.
M. tuberculosis grows at 37oC with a 5 to 10% CO2 mixture. It can be
distinguished from some atypical pathogens by its absence of growth at
room temperature, beading when stained from media, and propensity to
form cords on 7H11 agar.20 With a generation time of over 12 hours,
sample contamination and overgrowth by conventional bacteria is a
continuing challenge. Biochemical assays may be used to distinguish M.
tuberculosis from other members of the complex when molecular
methods are not specific, such as growth in niacin, positive nitrate
reduction test, and high-performance liquid chromatographic analysis.3
False-positive culture results may occur from laboratory contamination,
or misidentification of an atypical mycobacterium. Pretreatment with a
fluoroquinolone may delay diagnosis by more than 2 weeks, including
delays in culture positivity.21,22
The Orange County study outpaced CDC data on culture yields. Solid
media detected 3 of every 4 cases, but the BACTEC™ 12B detected 19
of every 20 cases (SENS 95%).8 Mean culture turnaround times were 18
days for BACTEC™ 12B, and over 30 days for the solid media. No single
modality captured all infections in this study.
Culture yields in extrapulmonary tuberculosis are significantly lower
than from sputum samples. Improvements in sample processing for use in
PCR have increased culture yields, resulting in detection of less than 102
organisms/mL.23,24 Pleural culture yields range from 23 to 67% from
fluid, and 90 to 97% from biopsy.25 Despite high yields, finding providers
to perform pleural biopsy is problematic.
All new culture isolates should be submitted for drug susceptibility
testing. This requires submission to referral centers, or special requests of
commercial laboratories.

Molecular Methods: NAA/PCR
NAA assays allow rapid turnaround time (24 to 48 hours) when samples
are smear positive and can be done on smear-negative specimens, but
with less sensitivity and specificity. They are performed directly on
specially processed specimens to provide simultaneous detection and
identification. Culture of the organism is still necessary to confirm the
identification and to perform drug-sensitivity tests. Molecular targets
usually include both an insertion sequence and a 16S rRNA sequence. A
recent comprehensive review on PCR utility is available.26 Direct PCR
tests must be explicitly ordered in most circumstances because of the
added costs of the amplification technique.
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Two FDA-approved molecular tests are available for rapid diagnosis: a
revised Amplified Mycobacterium Tuberculosis Direct Test (MTD) by
Gen-Probe, and the Mycobacterium Tuberculosis Test (MTT) by Amplicor.27 The Orange County study detected 9 of every 10 cases in 1 to 2
days with the revised MTD.8 PCR in sputum should be used to confirm
diagnosis on a smear-positive specimen, though it has been used in
primary diagnosis.28
Results in extrapulmonary testing demonstrate decreased sensitivity.
One method incorporating both devR and IS6110 primers yielded positive
results in two-thirds of cases of lymph node tuberculous disease.27
These are amplification tests. With positive culture material, a nonamplified sequence test can be performed. PCR sequences for M. avium
intracellulare and M. kansasii also are available.

Molecular Methods: Inflammatory Marker
Measurements
Inflammatory marker measurements exploit differences in the predominating immune response to different pathogens. Adenosine deaminase
(ADA) and interferon gamma (IFN-g) sometimes are used to diagnose
tuberculous effusions.29 Other inflammatory markers also have been
studied.30 These assays, too, may be compromised in immunocompromised patients.31 Combined PCR, ADA, and culture techniques have
been used.32,33
QuantiFERON®-TB Gold Test (QFT-G) is discussed for LTBI elsewhere in this compendium. It has been studied in large cohorts,34-36
including HIV patients.37 Relative anergy during active disease can
occur, though it may outperform TST.38,39 Other assays are under
development.40

Fluid Cell Counts and Chemistries, Nonspecific
Changes
Fluid analysis may provide helpful clues in the diagnosis of tuberculosis. Involved pleural, pericardial, and CSF fluid may manifest neutrophilia, although a lymphocytosis eventually predominates. Protein is
elevated and glucose levels may be low or low normal. Lactate dehydrogenase usually is elevated as effusions most often are exudative. Persistent sterile pyuria in an ill patient should raise suspicion for tuberculosis.
Detailed descriptions of extrapulmonary tuberculosis findings are published.41
A wide range of nonspecific findings also may suggest tuberculosis.
454
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These changes are more prevalent with worsening disease.42 In pulmonary disease, up to three-quarters of moderately ill patients will have
anemia with a low serum iron and total iron binding content, and
erythrocyte sedimentation rate elevation. Half to two-thirds of patients
will have a peripheral neutrophilia, monocytosis, and thrombocytosis.
Rarer findings include lymphopenia, leukopenia, folic acid deficiency,
macrocytic anemia, pancytopenia, and thrombocytopenia. Miliary disease
may manifest an elevation of alkaline phosphatase, normal or mildly
elevated hepatic transaminases and adrenal insufficiency.43

Summary
Laboratory diagnosis of tuberculosis requires a multimodality approach,
as well as recognition that empiric therapy often is appropriate. New
technologies such as proteomics and microarrays may soon find their
place in the evaluation of patients.44,45 However, sputum and tissue
analysis remain the cornerstone of laboratory diagnosis. Providers must
be aware of how their laboratories process specimens, and which tests are
an automatic part of evaluation. A direct PCR often must be requested
separately.
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